Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

Leukemia

Volumn 27, Issue 11, 2013, Pages 2157-2164

  Nomdedeu J F ^a   Hoyos, M ^b,c   Carricondo, M ^a   Bussaglia, E ^a   Estivill, C ^a   Esteve, J ^d   Tormo, M ^e   Duarte, R ^f   Salamero, O ^g   De Llano, M P Q ^h   Garcia A ⁱ   Bargay, J ^j   Heras, I ^k   Marti Tutusaus J M ^l   Llorente, A ^m   Ribera, J M ⁿ   Gallardo, D ^o   Aventin, A ^a   Brunet, S ^c   Sierra, J ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e Hospital Clinic   (Spain)

^f ICO Hospitalet   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ HOSPITAL ARNAU DE VILANOVA   (Spain)

^j HOSPITAL SON LLÀTZER   (Spain)

^k HOSPITAL MORALES MESEGUER   (Spain)

^l HOSPITAL MÚTUA DE TERRASSA   (Spain)

^m HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁿ ICO Badalona   (Spain)

^o Hematology Department ICO Josep Trueta   (Spain)

more..

Author keywords

minimal residual disease; molecular diagnostics; WT1

Indexed keywords

BUSULFAN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTARABINE; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY;

EID: 84887321618     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.111     Document Type: Article

References (36)

1. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341.
2. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121. (Pubitemid 35203456)
3. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 1988-1995. (Pubitemid 46606388)
4. Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I et al. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia 2007; 21: 1442-1450. (Pubitemid 46965285)
5. Chau YY, Hastie ND. The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet 2012; 28: 515-524.
6. Hosen N, Shirakata T, Nishida S, Yanagihara M, Tsuboi A, Kawakami M et al. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 2007; 21: 1783-1791. (Pubitemid 47086767)
7. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006; 15: (Spec No 2) R196-R201. (Pubitemid 44446794)
8. Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011; 11: 111-121.
9. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol 2010; 28: 13-19.
10. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
11. Cilloni D, Gottardi E, Fava M, Messa F, Carturan S, Busca A et al. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood 2003; 102: 773-774 (author reply 774).
12. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195-5201.
13. Lasa A, Carricondo M, Estivill C, Bussaglia E, Gich I, Brunet S et al. WT1 monitoring in core binding factor AML: comparison with specific chimeric products. Leuk Res 2009; 33: 1643-1649.
14. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008; 141: 782-791. (Pubitemid 351724866)
15. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 2004; 125: 590-600. (Pubitemid 38747961)
16. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416-1423. (Pubitemid 41148947)
17. Pozzi S, Geroldi S, Tedone E, Luchetti S, Grasso R, Colombo N et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013; 160: 503-509.
18. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008; 93: 921-924. (Pubitemid 351821731)
19. Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M et al. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leuk Res 2010; 35: 163-168.
20. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 2009; 102: 173-180.
21. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-2972.
22. Perea G, Lasa A, Aventin A, Domingo A, Villamor N, Queipo de Llano MP et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006; 20: 87-94.
23. Ogawa H, Tamaki H. The background level of WT1 expression following alloeneic stem cell transplantation is significantly decreased. Blood 2003; 102: 774.
24. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704. (Pubitemid 36237562)
25. Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944-4951.
26. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
27. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217-1225. (Pubitemid 27314159)
28. Barragan E, Cervera J, Bolufer P, Ballester S, Mart?́n G, Fernández P et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926-933. (Pubitemid 39049900)
29. Luesink M, Hollink IH, van der Velden VH, Knops RH, Boezeman JB, de Haas V et al. High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood 2012; 120: 2064-2075.
30. Furuhata A, Murakami M, Ito H, Gao S, Yoshida K, Sobue S et al. GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. Leukemia 2009; 23: 1270-1277.
31. Gaur GC, Ramadan SM, Cicconi L, Noguera NI, Luna I, Such E et al. Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol 2012; 91: 1855-1860.
32. Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol 2012; 96: 469-476.
33. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507-1515. (Pubitemid 46638771)
34. Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003; 123: 49-59. (Pubitemid 37222757)
35. Rossi G, Minervini MM, Carella AM, de Waure C, di Nardo F, Melillo L et al. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res 2011; 36: 401-406.
36. Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009; 23: 1472-1479.